Immunovaccine Signs Agreement with Vaxil BioTherapeutics to Advance Potential Cancer Vaccine
HALIFAX, NOVA SCOTIA -- (MARKET WIRE) -- 06/07/10 -- Immunovaccine Inc. (TSX VENTURE: IMV) today announced that it has signed a collaborative research agreement with Vaxil BioTherapeutics to explore the efficacy of Vaxil's cancer antigens in Immunovaccine's DepoVax vaccine enhancement platform.
"Vaxil has an innovative approach for identifying cancer antigens that get presented more efficiently by the MHC molecules. Vaxil's long peptides are good candidates for formulation in our DepoVax platform making this an interesting research partnership" remarked Dr. Marc Mansour, vice president of R&D at Immunovaccine.
"In preclinical studies, the DepoVax delivery platform has a demonstrated ability to enhance vaccines, generating a prolonged immune response. We believe that this could fit well with our products and we look forward to making strong advances together in developing the next generation of cancer therapeutics," said Dr. Lior Carmon, founder and CEO of Vaxil BioTherapeutics.
Vaxil BioTherapeutics, based in Israel, is a pioneer in the development of novel T-cell synthetic vaccines for both therapeutic and prophylactic use. Using a proprietary technology VaxHit the company has identified a large number of vaccine candidates in the fields of cancer and infectious diseases. The company's lead product - ImMucin, an anti-MUC1 therapeutic cancer vaccine has received regulatory permission to start Phase I/II clinical trials in Multiple Myeloma patients, due to commence in 2010. www.vaxilbio.com
Immunovaccine Inc. (TSX VENTURE: IMV), based in Canada, is a clinical stage vaccine development company focused on the commercialization of its patented DepoVax vaccine delivery technology. The company's lead product DPX-0907, a therapeutic cancer vaccine is in a Phase 1 clinical trial in the US. Immunovaccine continues to strengthen its vaccine pipeline, through licensing and strategic partnerships, to develop therapeutic cancer and infectious disease vaccines. www.imvaccine.com
This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts: Immunovaccine Inc. Dr. Marc Mansour Vice President R&D (902) 492-1819 [email protected] Immunovaccine Inc. Jennifer Ayotte Director Communications (902) 492-1819 [email protected] www.imvaccine.com Tiberend Strategic Advisors, Inc. Andrew Mielach (212) 827-0020 [email protected]
Released June 7, 2010